This is a National Phase Application in the United States of International Patent Application No. PCT/EP2005/012248 filed Nov. 15, 2005, which claims priority on European Patent Application No. 04028411.9, filed Dec. 1, 2004. The entire disclosures of the above patent applications are hereby incorporated by reference.
The present invention concerns an injection device and, in particular, a device for the intramuscular or subcutaneous injection of an active pharmaceutical principle.
In numerous cases, the parenteral administration of active pharmaceutical principles may be preferred to oral absorption, particularly when the medicine to be administered partially or totally decomposes in the digestive system or when a rapid response of the organism is sought.
Parenteral administration of medical principles has, however, certain drawbacks. One of these drawbacks lies in the discomfort experienced by the patient to whom the active principle is being administered. Indeed, parenteral preparations generally take the form of a large volume of liquid in which the medicine is in suspension or dissolved. When the medicine is not very soluble or difficult to pass into suspension, or even when the active principle has to be administered in large doses, a relatively large volume of liquid has to be injected. The ratio between the active principle and the excipient is usually comprised between one percent and one per thousand. The discomfort experienced by the patient thus results both from the size of the needle and the volume of liquid to be injected. In some cases, the very nature of the excipient can also cause the patient suffering.
Another drawback of administering medicine dissolved or in suspension in a liquid medium lies in the fact that the medicine is often unstable in the liquid. The medicine and the liquid must thus be mixed shortly prior to the injection. This can prove particularly disadvantageous when, for example, hundreds of people have to be treated in a small period of time to wipe out an epidemic (administration of a vaccine).
In order to overcome the aforementioned drawbacks, medicines in solid rather than liquid form have been used in order to develop slow release or controlled release preparations. The preparation takes the form of an implant or a rod that is directly injected using a trocar. This type of implant has to enclose the daily dose of medicine multiplied by the number of days of activity, and the quantity of medium sufficient to control the speed of release of the medicine for the time period concerned. Consequently, these solid preparations for injection require a much larger needle than the needles ordinarily used with syringes, which leads to painful injections.
The security injection device disclosed in European Patent No. 0 783 342 overcomes this last drawback. It will be briefly described in conjunction with
Designated as a whole by the general reference numeral 1, the injection device shown in
The operation of injection device 1 briefly described above is as follows. When the device is pressed against the patient's skin, sheath 12 slides over body 2, thereby exposing needle 4 and allowing the latter to penetrate the skin, while piston 18 and rod 8, arranged as to be able to slide, hold the medicine under the skin when needle 4 is removed.
The solid medicine to be injected is for immediate assimilation by the body. Thus, since the injected quantities are only those necessary to obtain an immediate effect, the needle can be as fine as those of conventional syringes. The injection is less painful insofar as the volume injected is considerably less than the volume necessary for an injection in liquid form. Moreover, the needle of the injection device is not exposed to external elements. Consequently, the needle cannot collect contaminating agents present in the atmosphere or prick anyone inadvertently. Likewise, it is not possible to inadvertently inject a fraction of the medicine or the patient's blood into a member of hospital personnel.
A seal 22 can seal aperture 24 via which needle 4 emerges from injection device 1 in order to preserve the sterility of said needle 4 and the medicinal dose 10. This seal 22 can be made of a brittle material such as biocompatible and biodegradable wax. Alternatively, aperture 24 can be sealed using a cap completely covering sleeve 12.
These means for sealing injection device 1 are not satisfactory. In the case of a wax cap, since there is a non-negligible risk of some of the material remaining caught on the needle and injected into the patient's skin, the manufacturer has to demonstrate the absence of any interaction between the wax and the injected medicine. In the case of a cap, there is a risk of the implant falling at the moment when the said cap is removed.
There therefore existed a need, in the state of the art, for means of preventing the implant falling prior to use of the injection device, particularly during periods of storage and during handling of said injection device prior to carrying out the actual injection.
It is an object of the present invention to answer this need in addition to others by providing an injection device for injecting a solid medicine, including a body inside which there moves a bevelled needle, into which the medicine is introduced, this injection device further including retaining means for preventing the medicine falling prior to injection, characterized in that the medicine is retained via an elastic deformation of the needle imparted by the retaining means or via an elastic deformation of the retaining means themselves, or via a combination of the flexibility of these two means.
Owing to these features, the present invention provides a device for injecting a solid medicine also called an implant, which can be handled without any excessive precautions without any risk of the implant falling out. In particular, if the open end of the injection device via which the needle exits is sealed with a cap, it is possible, when preparing to carry out the injection, to remove the cap without any fear of the implant falling out. Moreover, since use is made of the elasticity of the needle and/or the retaining means, there is no need to resort to complicated manipulations in order to remove said retaining means before being able to use said device. Moreover, the retaining means do not interfere in any way with the proper operation of the injection device.
According to a complementary feature of the invention, the retaining means temporarily seal the needle bevel in the rest position, thereby preventing the implant from exiting the needle and falling out.
According to a first embodiment of the invention, the retaining means move the aperture through which the needle exits off-centre relative to the general axis of forward movement of said needle inside the injection device.
According to a second embodiment, the retaining means include an elastic tongue that temporarily abuts against the needle bevel.
Other features and advantages of the present invention will appear more clearly from the following detailed description of two embodiments of the injection device according to the invention, these examples being given purely by way of non-limiting illustration, in conjunction with the annexed drawing, in which:
The present invention proceeds from the general inventive idea that consists in fitting a device for injecting a solid medicine also called an implant with means for preventing the medicine falling out during periods of storage or just before the injection is carried out. By employing the elasticity of the needle or their own elasticity, these means do not require the user to resort to complicated manipulations to make said device operational. Moreover, while guaranteeing that the implant will not fall out in the rest position of the needle, the retaining means according to the invention in no way interfere with the exit of the needle and the general proper operation of the injection device.
A first embodiment of the retaining means according to the invention is illustrated in
The distal end 26 of body 2 of the injection device is profiled with an insert 28. This insert 28 is made of a biocompatible plastic material that can be sterilised for example by irradiation, such as a polycarbonate. It is introduced inside body 2 via aperture 24 through which needle 4 exits. Insert 28, of generally cylindrical shape, has an external diameter adapted to the inner diameter of body 2, such that the friction forces between these two parts is sufficient to prevent any risk of said insert 28 inadvertently falling out.
As can be seen upon examining the Figures, insert 28 includes at the base thereof an aperture 30 through which needle 4 exits. This aperture 30 is off-centre relative to the general axis of forward movement X-X of needle 4. Insert 28 thus has, on the face thereof opposite said needle 4, an inclined plane 32, which, from top to bottom, moves closer to the axis of forward movement of said needle 4 until it intercepts the latter and leads to aperture 30. Thus, in the rest position (
A second embodiment of the retaining means according to the invention is shown in
Insert 38 has two through apertures 40 and 42 aligned on the general axis of forward movement X-X of needle 4 inside body 2. The first of these apertures 40 allows needle 4 to exit body 2 of the injection device at the moment that the injection is carried out (see
It goes without saying that the present invention is not limited to the embodiments that have just been described and that various simple alterations and variants could be envisaged by those skilled in the art without departing from the scope of the invention as defined by the annexed claims.
Number | Date | Country | Kind |
---|---|---|---|
04028411 | Dec 2004 | EP | regional |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/EP2005/012248 | 11/15/2005 | WO | 00 | 5/11/2009 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2006/058614 | 6/8/2006 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3016895 | Sein | Jul 1962 | A |
3809298 | Harris et al. | May 1974 | A |
4701164 | Cassou et al. | Oct 1987 | A |
4850968 | Romano | Jul 1989 | A |
4881551 | Taylor | Nov 1989 | A |
4900303 | Lemelson | Feb 1990 | A |
4941874 | Sandow et al. | Jul 1990 | A |
4950234 | Fujioka et al. | Aug 1990 | A |
5019049 | Haining | May 1991 | A |
5090962 | Landry et al. | Feb 1992 | A |
5098402 | Davis | Mar 1992 | A |
5141500 | Hake | Aug 1992 | A |
5147303 | Martin | Sep 1992 | A |
5176643 | Kramer et al. | Jan 1993 | A |
5273541 | Malenchek | Dec 1993 | A |
5284479 | de Jong | Feb 1994 | A |
5300079 | Niezink et al. | Apr 1994 | A |
5304152 | Sams | Apr 1994 | A |
5370620 | Shonfeld | Dec 1994 | A |
5522804 | Lynn | Jun 1996 | A |
5542920 | Cherif Cheikh | Aug 1996 | A |
5562613 | Kaldany | Oct 1996 | A |
5632729 | Cai et al. | May 1997 | A |
5695463 | Cherif-Cheikh | Dec 1997 | A |
5823994 | Sharkey et al. | Oct 1998 | A |
5984890 | Gast et al. | Nov 1999 | A |
6049301 | Weagant | Apr 2000 | A |
6056726 | Isaacson | May 2000 | A |
6179812 | Botich et al. | Jan 2001 | B1 |
6228049 | Schroeder et al. | May 2001 | B1 |
6402716 | Ryoo et al. | Jun 2002 | B1 |
6478768 | Kneer | Nov 2002 | B1 |
6478790 | Bardani | Nov 2002 | B2 |
6605073 | Pressly et al. | Aug 2003 | B1 |
6752782 | Liao | Jun 2004 | B2 |
6896670 | Cherif Cheikh | May 2005 | B2 |
6905478 | Ingram et al. | Jun 2005 | B2 |
7329235 | Bertron et al. | Feb 2008 | B2 |
7500964 | Shaw et al. | Mar 2009 | B2 |
7798988 | Aubert et al. | Sep 2010 | B2 |
20020161337 | Shaw et al. | Oct 2002 | A1 |
20020193747 | Denolly | Dec 2002 | A1 |
20030004457 | Andersson | Jan 2003 | A1 |
20030040699 | Talling et al. | Feb 2003 | A1 |
20030125669 | Safabash et al. | Jul 2003 | A1 |
20030233101 | Lubock et al. | Dec 2003 | A1 |
20050101967 | Weber et al. | May 2005 | A1 |
20050159709 | Wilkinson | Jul 2005 | A1 |
20080249466 | Aubert et al. | Oct 2008 | A1 |
Number | Date | Country |
---|---|---|
0 596 162 | May 1994 | EP |
0783342 | Nov 1998 | EP |
1 666 185 | Jul 2006 | EP |
Number | Date | Country | |
---|---|---|---|
20090270797 A1 | Oct 2009 | US |